NEW HAVEN, Conn., Nov. 2  /PRNewswire/ -- RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, will be presenting, at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 2:20 p.m., eastern.

RHEI Pharmaceuticals provides a matchless turnkey solution for any company wishing to gain access to the fastest growing market in the world. The company is actively seeking both new investors and new products for the China market.

RHEI in-licenses proprietary pharmaceuticals for the China market and utilizes its network of experienced clinicians to achieve expedited market approval and commercialization. RHEI is unique in having successfully integrated a full pharmaceutical operation in China and in its acquisition of approved and late-stage western pharmaceuticals that address the special needs of the China healthcare market. RHEI's nationwide salesforce in China, led by Big Pharma experienced sales and marketing executives, applies western pharmaceutical marketing practices focusing on key opinion leaders (KOLs) within the major hospitals throughout China.

RHEI will be represented at the Rodman & Renshaw conference by its Chairman, Harry H. Penner, Jr., and its VP Commercial Operations, Scott Kozak.

About RHEI Pharmaceuticals

RHEI Pharmaceuticals is a venture backed specialty pharmaceuticals company with operations in the U.S. and in China that acquires, licenses, develops and commercializes in China proprietary drug therapies based upon the unmet needs of the emerging China pharmaceuticals market. RHEI specializes in hospital- based proprietary products with a therapeutic focus on urgent unmet needs in the areas of cancer, cardiovascular disease, neurology, anti-infectives, and other life threatening conditions.